Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LNG099
MIFTS: 60

Lung Disease

Categories: Blood diseases, Respiratory diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Lung Disease

About this section

MalaCards integrated aliases for Lung Disease:

Name: Lung Disease 12 15 17
Lung Diseases 54 42 43 15 71

Classifications:

MalaCards categories:
Anatomical: Respiratory diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:850
MeSH 43 D008171
NCIt 49 C3198
SNOMED-CT 67 19829001
ICD10 32 J60-J70 J98.4
UMLS 71 C0024115
Sources

Summaries for Lung Disease

About this section
MedlinePlus : 42 When you breathe, your lungs take in oxygen from the air and deliver it to the bloodstream. The cells in your body need oxygen to work and grow. During a normal day, you breathe nearly 25,000 times. People with lung disease have difficulty breathing. Millions of people in the U.S. have lung disease. If all types of lung disease are lumped together, it is the number three killer in the United States. The term lung disease refers to many disorders affecting the lungs, such as asthma, COPD, infections like influenza, pneumonia and tuberculosis, lung cancer, and many other breathing problems. Some lung diseases can lead to respiratory failure. Dept. of Health and Human Services Office on Women's Health

MalaCards based summary : Lung Disease, also known as lung diseases, is related to interstitial lung disease and rheumatoid arthritis interstitial lung disease, and has symptoms including dyspnea, hemoptysis and apnea. An important gene associated with Lung Disease is SFTPC (Surfactant Protein C), and among its related pathways/superpathways are Metabolism of proteins and Toll-like Receptor Signaling Pathway. The drugs Caspofungin and Ropivacaine have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and heart, and related phenotypes are homeostasis/metabolism and hematopoietic system

Disease Ontology : 12 A lower respiratory tract disease in which the function of the lungs is adversely affected by narrowing or blockage of the airways resulting in poor air flow, a loss of elasticity in the lungs that produces a decrease in the total volume of air that the lungs are able to hold, and clotting, scarring, or inflammation of the blood vessels that affect the ability of the lungs to take up oxygen and to release carbon dioxide.

Sources

Related Diseases for Lung Disease

About this section

Diseases related to Lung Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1286)
# Related Disease Score Top Affiliating Genes
1 interstitial lung disease 35.5 TNF TERT SFTPD SFTPC SFTPB MUC5B
2 rheumatoid arthritis interstitial lung disease 34.9 TNF SFTPD
3 nontuberculous mycobacterial lung disease 34.8 TNF CFTR
4 pulmonary disease, chronic obstructive 34.4 TNF SFTPD SFTPB SERPINA1 MUC5B IL1B
5 interstitial pneumonitis, desquamative, familial 34.3 SFTPD SFTPC SFTPB SFTPA2 MUC5B ABCA3
6 surfactant dysfunction 34.1 SFTPC SFTPB SFTPA1 ABCA3
7 pneumoconiosis 33.9 TNF SERPINA1 MUC5B IL1B CXCL8
8 pulmonary fibrosis, idiopathic 33.9 TNF TERT SFTPD SFTPC SFTPB SFTPA2
9 extrinsic allergic alveolitis 33.9 SFTPD IL1B ELANE CXCL8
10 pulmonary fibrosis 33.9 TERT SFTPD SFTPC SFTPA2 SFTPA1 MUC5B
11 surfactant metabolism dysfunction, pulmonary, 1 33.8 SFTPB ABCA3
12 alpha-1-antitrypsin deficiency 33.8 TNF SERPINA1 ELANE CXCL8 CFTR
13 cystic fibrosis 33.7 TNF SFTPD SFTPC SERPINA1 MUC5B IL1B
14 idiopathic interstitial pneumonia 33.7 SFTPD SFTPC SFTPB SFTPA2 SFTPA1 MUC5B
15 respiratory failure 33.6 TNF SFTPD SFTPC SFTPB SERPINA1 IL1B
16 silicosis 33.6 TNF SFTPD IL1B CXCL8
17 pulmonary hypertension 33.5 TNF SFTPC IL1B ELANE CXCL8
18 aspergillosis 33.5 TNF SFTPD SFTPA2 SFTPA1 IL1B ELANE
19 bronchopulmonary dysplasia 33.5 SFTPB ELANE CXCL8
20 bronchiolitis 33.3 TNF SFTPD CXCL8
21 antisynthetase syndrome 33.3 MUC5B IL1B
22 bagassosis 33.3 IL1B CXCL8
23 asthma 33.3 TNF SFTPD SERPINA1 IL1B ELANE CXCL8
24 pulmonary alveolar microlithiasis 33.3 SFTPD SFTPA2 ABCA3
25 pneumonia 33.3 TNF SFTPD SFTPC SFTPB SERPINA1 MUC5B
26 cryptogenic organizing pneumonia 33.3 TNF SFTPD SFTPC CXCL8
27 pulmonary alveolar proteinosis 33.2 TNF SFTPD SFTPC SFTPB SFTPA1 CXCL8
28 mycobacterium abscessus 33.2 TNF SERPINA1 CXCL8 CFTR
29 allergic bronchopulmonary aspergillosis 33.2 SFTPD SFTPA2 SFTPA1 CFTR
30 respiratory distress syndrome in premature infants 33.2 SFTPC SFTPB SFTPA1 ABCA3
31 bronchiolitis obliterans 33.2 TNF SFTPD CXCL8
32 pleural disease 33.0 TNF IL1B CXCL8
33 pulmonary hemosiderosis 32.9 SFTPB ABCA3
34 bronchiectasis 32.5 TNF SERPINA1 IL1B ELANE CXCL8 CFTR
35 bronchitis 32.5 TNF SERPINA1 IL1B ELANE CXCL8 CFTR
36 connective tissue disease 32.4 TNF SFTPD IL1B FLNA CXCL8
37 nonspecific interstitial pneumonia 32.4 SFTPD SFTPC MUC5B IFIH1 ABCA3
38 myositis 32.1 TNF IL1B IFIH1 CXCL8
39 lipid pneumonia 32.0 SFTPB ABCA3
40 pulmonary emphysema 31.9 SFTPD SFTPC SERPINA1 ELANE CXCL8
41 gastroesophageal reflux 31.9 TNF TERT IL1B ELANE CXCL8
42 acute interstitial pneumonia 31.8 SFTPD SFTPC SFTPB SFTPA2 IFIH1 ABCA3
43 pulmonary edema 31.8 TNF IL1B CXCL8 CFTR
44 newborn respiratory distress syndrome 31.7 SFTPD SFTPC SFTPB SFTPA2 SFTPA1 IL1B
45 exanthem 31.7 TNF IL1B IFIH1 CXCL8
46 lung cancer susceptibility 3 31.7 TSC2 TERT SFTPD SFTPC SFTPB SERPINA1
47 adult respiratory distress syndrome 31.7 TNF SFTPD SFTPC SFTPB IL1B ELANE
48 haemophilus influenzae 31.7 TNF CXCL8
49 bacterial pneumonia 31.6 TNF SFTPD SFTPB IL1B ELANE CXCL8
50 proteasome-associated autoinflammatory syndrome 1 31.6 TNF IL1B ELANE CXCL8

Graphical network of the top 20 diseases related to Lung Disease:



Diseases related to Lung Disease
Sources

Symptoms & Phenotypes for Lung Disease

About this section

UMLS symptoms related to Lung Disease:


dyspnea, hemoptysis, apnea, snoring, coughing, labored breathing

MGI Mouse Phenotypes related to Lung Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.17 ABCA3 CFTR ELANE FLNA IFIH1 IL1B
2 hematopoietic system MP:0005397 10.11 CFTR ELANE FLNA IFIH1 IL1B MUC5B
3 mortality/aging MP:0010768 10.06 ABCA3 CFTR ELANE FLNA IFIH1 IL1B
4 immune system MP:0005387 10.03 CFTR ELANE FLNA IFIH1 IL1B ITGA3
5 neoplasm MP:0002006 9.5 ELANE IL1B ITGA3 SFTPC TERT TNF
6 respiratory system MP:0005388 9.36 ABCA3 CFTR FLNA ITGA3 MUC5B SFTPA1
Sources

Drugs & Therapeutics for Lung Disease

About this section

Drugs for Lung Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 777)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Caspofungin Approved Phase 4 162808-62-0, 179463-17-3 2826718 468682
2
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
3
Cefuroxime Approved Phase 4 55268-75-2 5479529 5361202
4
Penicillin G Approved, Vet_approved Phase 4 61-33-6 5904
5
Morphine Approved, Investigational Phase 4 57-27-2 5288826
6
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
7
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
8
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
9
Polyestradiol phosphate Approved Phase 4 28014-46-2
10
Riociguat Approved Phase 4 625115-55-1
11
Ledipasvir Approved Phase 4 1256388-51-8 67505836
12
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
13
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
14
Phenylephrine Approved Phase 4 59-42-7 6041
15
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
16
Montelukast Approved Phase 4 158966-92-8 5281040
17
Propranolol Approved, Investigational Phase 4 525-66-6 4946
18
Theophylline Approved Phase 4 58-55-9 2153
19
Aztreonam Approved Phase 4 78110-38-0 5742832 5362041
20
Ambrisentan Approved, Investigational Phase 4 177036-94-1 6918493
21
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
22
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
23
Simvastatin Approved Phase 4 79902-63-9 54454
24 Orange Approved Phase 4
25
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
26
Norflurane Approved, Experimental Phase 4 811-97-2
27
Fosinopril Approved Phase 4 98048-97-6 55891
28
Iloprost Approved, Investigational Phase 4 78919-13-8 6443959
29
Bisoprolol Approved Phase 4 66722-44-9 2405
30
Celiprolol Approved, Investigational Phase 4 56980-93-9
31
Ciclesonide Approved, Investigational Phase 4 141845-82-1, 126544-47-6 444033
32
Fluconazole Approved, Investigational Phase 4 86386-73-4 3365
33
Anidulafungin Approved, Investigational Phase 4 166663-25-8 166548
34
Sultamicillin Approved, Investigational Phase 4 76497-13-7
35
Ketoconazole Approved, Investigational Phase 4 65277-42-1 47576
36
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
37
Dobutamine Approved Phase 4 34368-04-2 36811
38
Metformin Approved Phase 4 657-24-9 14219 4091
39
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
40
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
41
Atorvastatin Approved Phase 4 134523-00-5 60823
42
Desflurane Approved Phase 4 57041-67-5 42113
43
Ergotamine Approved Phase 4 113-15-5 8223
44
Sumatriptan Approved, Investigational Phase 4 103628-46-2 5358
45
Nortriptyline Approved Phase 4 72-69-5 4543
46
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
47
Bisacodyl Approved Phase 4 603-50-9
48
Prucalopride Approved Phase 4 179474-81-8
49
Histamine Approved, Investigational Phase 4 51-45-6 774
50 Ancrod Approved, Investigational Phase 4 9046-56-4

Interventional clinical trials:

(show top 50) (show all 4748)
# Name Status NCT ID Phase Drugs
1 Antibiotic Treatment of Patients With Chronic Obstructive Lung Disease: A Prospective, Randomized, Double-Blind Placebo-Controlled Study of Intermittent, Prophylactic Antibiotic Treatment With Azithromycin Unknown status NCT00132860 Phase 4 azithromycin
2 Randomized Controlled Trial of Pirfenidone in Patients With Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis Unknown status NCT02821689 Phase 4 Pirfenidone
3 Comparison of Efficacy Different Treatment Regimens in Pulmonary Hypertension Secondary to Lung Disease and or Hypoxia Unknown status NCT01449253 Phase 4 Sildenafil;Bosentan
4 Use of the Endothelin-1 Antagonist Bosentan in Patients With Established Pulmonary Hypertension and Fibrotic Lung Disease. - A Randomised, Placebo-Controlled, Double-Blinded Study. Unknown status NCT00637065 Phase 4 Bosentan;Placebo
5 Prevention of Chronic Lung Disease (CLD) in Preterm Infants -A New Therapeutic Regimen Unknown status NCT00883532 Phase 4 budesonide;surfactant and air (placebo)
6 Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients Unknown status NCT01382368 Phase 4 Sildenafil
7 Pulmonary Effects of the Combination of Metoprolol and Formoterol in COPD Unknown status NCT00288548 Phase 4 Metoprolol
8 Efficacy and Safety of Tulobuterol Patch Combined With Tiotropium Bromide for Relieving Dyspnea Symptom of Chronic Obstructive Pulmonary Disease Unknown status NCT01465906 Phase 4 tulobuterol;Tiotropium Bromide;tiotropium bromide
9 Doxycycline and Airway Inflammation in COPD: A Randomised Placebo Controlled Trial Studying the Effects of Doxycycline on Airway Inflammation in Patients With Moderate and Severe Stable COPD. Unknown status NCT00857038 Phase 4 Doxycycline;Placebo
10 Seasonal Influenza Vaccine, Quadrivalent Versus Trivalent in Patients With Advanced Chronic Obstructive Pulmonary Disease Unknown status NCT02563184 Phase 4
11 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Roflumilast on Endothelial Function in Patients With Chronic Obstructive Pulmonary Disease Unknown status NCT01595750 Phase 4 Roflumilast 500;Placebo
12 Prospective, Open-label Study of the Efficacy and Safety of Caspofungin for the Treatment of Invasive Pulmonary Aspergillosis Underlying Chronic Obstructive Pulmonary Disease Unknown status NCT01499433 Phase 4 caspofungin
13 An Efficacy Study of Benzalkonium Chloride Solution Clearing the Oral Colonized Bacterium in Hospitalized Patients With COPD Unknown status NCT02269800 Phase 4 Benzalkonium chloride solution;Normal saline
14 Utility of the AeriSeal System in Patients With Advanced Upper Lobe Predominant Emphysema and Collateral Ventilation Assessed by the Chartis System Unknown status NCT01460108 Phase 4
15 Differences of Small Airways Function Between Chronic Obstructive Pulmonary Disease(COPD) and Asthma-copd Overlap(ACO) Unknown status NCT03563001 Phase 4 Budesonide(160ug) and Formoterol(4.5ug) bid
16 Impact of Exercise on Lung Function in Patients With Chronic Obstructive Pulmonary Disease Unknown status NCT03551197 Phase 4 Budesonide and formoterol bid
17 Effects of Exercise Training on Systemic Inflammation an Muscle Repair According to the Chronic Obstructive Pulmonary Disease Phenotype Unknown status NCT01431625 Phase 4
18 Long-Term Oxygen Therapy (LTOT) in Chronic Obstructive Pulmonary Disease (COPD) Patients With Moderate Chronic Hypoxemia and Chronic Heart Failure (CHF) Unknown status NCT00668408 Phase 4
19 Inspiratory Capacity and HRCT Comparison of Nebulized Arformoterol (Brovana) vs. Dry-powder Inhaler Salmeterol (Serevent) Unknown status NCT01361984 Phase 4 Nebulized arformoterol;Salmeterol
20 The Lung Attack Alert Study Unknown status NCT01107613 Phase 4
21 Comparing Treatment Efficacy With High and Medium Dose of Fluticasone in Combination With Salmeterol in COPD Patients Unknown status NCT01131806 Phase 4 fluticasone/ salmeterol 125/25 mcg/puff;fluticasone/ salmeterol 250/25 mcg/puff
22 A Multi-Center, Prospective, Clinical Trial Designed to Study the Efficacy of One-Way Valve Implantation Based on a New Treatment Algorithm in Patients With Heterogeneous Emphysema Unknown status NCT00730301 Phase 4
23 Adherence to Therapy in COPD Patients Under Dose Escalation of Roflumilast Unknown status NCT02018432 Phase 4 Roflumilast escalation dosage;Roflumilast conventional dosage
24 Evaluate the Efficacy of Xuebijing Injection in Acute Exacerbations of COPD：a Multicentre Randomised Controlled Trial Unknown status NCT02937974 Phase 4 Xuebijing;Placebo
25 Suprascapular Nerve Block as Postoperative Analgesia After Artroscopic Shoulder Surgery - a Randomized, Blinded, Placebo Controlled Study Unknown status NCT02576223 Phase 4 Ropivacaine hydrochloride;Isotonic Saline
26 Efficacy and Safety of Salmeterol/Fluticasone Propionate vs Ipratropium/Albuterolin Chinese Patients With Moderate-to-severe COPD. Unknown status NCT01243788 Phase 4 Salmeterol/Fluticasone Propionate
27 Effects of Nutritional Supplementation in Malnourished Patients in Stable COPD:a Randomised Controlled Trial Unknown status NCT02197871 Phase 4
28 Utilizing Wearable Device to Observe the Clinical Response of COPD Patients Treated With Combined Bronchodilator and Home-based Pulmonary Rehabilitation Program Unknown status NCT03364829 Phase 4 Indacaterol/Glycopyrronium
29 Different Reintroduction Regimens of Antituberculosis Drugs After Development of Hepatitis During Anti-tuberculosis Treatment Unknown status NCT01395654 Phase 4 isoniazid, rifampin, pyrazinamide
30 Inspiratory Muscle Training for Dyspneic Patients With COPD-HF Overlap: a Multicenter, Randomized Controlled Trial Unknown status NCT02579200 Phase 4
31 Effect of Intravenous Iron (Ferinject®) on Exercise Capacity and Quality of Life of Stable COPD Patients Unknown status NCT02416778 Phase 4 Ferric carboxymaltose, Ferinject® 50mg Iron/ml Solution for Injection / Infusion
32 Non-Invasive Positive Pressure Mask Ventilation vs Extrathoracic Biphasic Cuirass Ventilation in Patients With Acute Respiratory Failure: A Randomized Prospective Study. Unknown status NCT00331656 Phase 4
33 The Effects of Simvastatin in Patients With Chronic Obstructive Pulmonary Disease Unknown status NCT00680641 Phase 4 Simvastatin;Placebo
34 Exacerbation's Prevention in Patients With COPD in GOLD IV Stage (Very Severe) With Non Invasive Mechanical Ventilation Unknown status NCT01481727 Phase 4
35 Description of the Ability to Learn How to Handle Inhaler Devices in COPD Unknown status NCT02813200 Phase 4 Seretide® Diskus® 500/550 μg;Ultibro® Breezhaler® 110/50 μg;Spiriva® Respimat® 2,5 μg
36 Interstitial Fibrosis in Protocol Biopsies of Renal Allografts: A Prospective, Randomised Trial of Sirolimus Versus Cyclosporine.(Fibrasic) Unknown status NCT00493194 Phase 4 sirolimus;cyclosporine;daclizumab
37 Pulmonary Gas Exchange Response to Indacaterol in Stable Symptomatic Chronic Obstructive Pulmonary Disease Patients Unknown status NCT02547558 Phase 4 Indacaterol
38 Inhaled Iloprost for Disproportionate Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease Unknown status NCT01116063 Phase 4 Inhaled iloprost
39 Improving Inhaler Treatment and Small Airways Assessment in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT01721291 Phase 4 SALBUTAMOL
40 Procalcitonin as a Marker of Antibiotic Therapy in Patients With Lower Respiratory Tract Infections. Can Measurement of Procalcitonin Reduce the Use of Antibiotics? Unknown status NCT02171338 Phase 4
41 International Multicenter Trial for the Evaluation of a Four-Drug Fixed Dose Combined Tablet Daily in the Initial Intensive Phase of Chemotherapy Followed by a Two-Drug Fixed Dose Combined Tablet Three Times a Week in the Continuation Phase for the Treatment of Pulmonary Tuberculosis Unknown status NCT00216333 Phase 4 combined fixed dose combination
42 Evaluation and Treatment of Small Airways in COPD Unknown status NCT02526758 Phase 4 beclomethasone;formoterol;budesonide
43 Banlangen Granules Anti-seasonal Influenza Study: a Randomized, Double Blind, Positive and Placebo Controlled，Clinical Study. Unknown status NCT02232945 Phase 4 placebo of oseltamivir phosphate;oseltamivir phosphate;Banlangen (Radix Isatidis) granules;placebo of Banlangen(Radix Isatidis) granules
44 A Multicentre, Randomized, Clinical Trial of Noninvasive Ventilation: Neurally Adjusted Ventilatory Assist (NAVA) vs. Pressure Support in Pediatric Acute Respiratory Failure - NINAVAPed Protocol Unknown status NCT01873521 Phase 4
45 Metformin for Weight Control in Adolescents Taking Atypical Antipsychotics- Double Blind Placebo Controlled Study Unknown status NCT00845936 Phase 4 Metformin
46 Advair - CRP Study Unknown status NCT00120978 Phase 4 Advair;Flovent
47 PET/CT and Roentgen in Lung Cancer. Evaluation of Patients in General Practice Unknown status NCT00675168 Phase 4
48 Phase IV Study of the Quantiferon-RD1 Test Unknown status NCT00311220 Phase 4 tuberculin for skin test
49 Bronchiolitis All-study, SE-Norway What is the Optimal Inhalation Treatment for Children 0-12 Months With Acute Bronchiolitis? Unknown status NCT00817466 Phase 4 Racemic adrenaline;Isotonic saline
50 Efficacy of Clarithromycin Treatment in Prevention of Chronic Lung Disease in Premature Infants Completed NCT01326611 Phase 4 Clarithromycin;Dextrose

Search NIH Clinical Center for Lung Disease

Cochrane evidence based reviews: lung diseases

Sources

Genetic Tests for Lung Disease

About this section
Sources

Anatomical Context for Lung Disease

About this section

MalaCards organs/tissues related to Lung Disease:

40
Lung, Testes, Heart, Neutrophil, Bone, Endothelial, T Cells
Sources

Publications for Lung Disease

About this section

Articles related to Lung Disease:

(show top 50) (show all 42726)
# Title Authors PMID Year
1
Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. 42
32376398 2020
2
Plants derived therapeutic strategies targeting chronic respiratory diseases: Chemical and immunological perspective. 42
32376238 2020
3
Acute respiratory failure in COVID-19: is it "typical" ARDS? 42
32375845 2020
4
Decreased Cyp2E1 mRNA expression in human leucocytes in patients with fibrotic and inflammatory lung diseases. 54 61
20514434 2010
5
Surfactant protein (SP)-A and SP-D as antimicrobial and immunotherapeutic agents. 54 61
20230362 2010
6
Adalimumab-induced acute pneumonitis in a patient with rheumatoid arthritis. 54 61
20511978 2010
7
Repression of IP-10 by interactions between histone deacetylation and hypermethylation in idiopathic pulmonary fibrosis. 54 61
20404089 2010
8
Characteristics of disorders associated with genetic mutations of surfactant protein C. 61 54
20403820 2010
9
Cytokine-dependent balance of mitogenic effects in primary human lung fibroblasts related to cyclic AMP signaling and phosphodiesterase 4 inhibition. 54 61
20082309 2010
10
Nrf2 protects against airway disorders. 61 54
19646463 2010
11
The NF-kappaB signaling in cystic fibrosis lung disease: pathophysiology and therapeutic potential. 54 61
20423679 2010
12
Lack of correlation between pulmonary disease and cystic fibrosis transmembrane conductance regulator dysfunction in cystic fibrosis: a case report. 54 61
20420703 2010
13
Long-term stability and circadian variation in circulating levels of surfactant protein D. 54 61
19540617 2010
14
Proline-Glycine-Proline (PGP) and High Mobility Group Box Protein-1 (HMGB1): Potential Mediators of Cystic Fibrosis Airway Inflammation. 61 54
20448817 2010
15
Assessment of alveolar epithelial permeability with Tc-99m DTPA aerosol scintigraphy in patients with Sjogren syndrome. 54 61
19582462 2010
16
Airway proteins involved in bacterial clearance susceptible to cathepsin G proteolysis. 61 54
19679607 2010
17
Lack of association of immune-response-gene polymorphisms with susceptibility to sarcoidosis in Slovenian patients. 54 61
20082271 2010
18
Alpha1-antitrypsin deficiency: forgotten etiology. 61 54
20090075 2010
19
Clara cell secretory protein in tracheobronchial aspirates and umbilical cord serum of extremely premature infants with systemic inflammation. 54 61
19887851 2010
20
Development of carbohydrate-derived inhibitors of acid sphingomyelinase. 54 61
20005726 2010
21
4-Oxo-beta-lactams (azetidine-2,4-diones) are potent and selective inhibitors of human leukocyte elastase. 54 61
19904934 2010
22
Anti-proline-glycine-proline or antielastin autoantibodies are not evident in chronic inflammatory lung disease. 61 54
19762563 2010
23
Generation of novel AAV variants by directed evolution for improved CFTR delivery to human ciliated airway epithelium. 54 61
19603002 2009
24
TNFalpha-induced GM-CSF release from human airway smooth muscle cells depends on activation of an ET-1 autoregulatory positive feedback mechanism. 61 54
19850966 2009
25
Surfactant protein C in canine pulmonary fibrosis. 61 54
19747194 2009
26
Early subcutaneous administration of etanercept (Enbrel) prevents from hyperoxia-induced lung injury. 61 54
19916860 2009
27
Prevalence and clinical significance of auto-antibodies in adults with cystic fibrosis. 54 61
19443536 2009
28
Pulmonary nodulosis and aseptic granulomatous lung disease occurring in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha-blocking agent: a case series. 61 54
19797509 2009
29
Expression and activity of phosphodiesterase isoforms during epithelial mesenchymal transition: the role of phosphodiesterase 4. 61 54
19759179 2009
30
Methemoglobin to cumulative nitric oxide ratio and response to inhaled nitric oxide in PPHN. 61 54
19554014 2009
31
Histone deacetylase-2 and airway disease. 61 54
19812111 2009
32
alpha1-Antitrypsin deficiency: best clinical practice. 61 54
19783716 2009
33
Long-acting local anesthetics attenuate FMLP-induced acute lung injury in rats. 54 61
19690261 2009
34
Serum levels of nicotinamide N-methyltransferase in patients with lung cancer. 54 61
19242722 2009
35
Natriuretic peptides for the prediction of severely impaired peak VO2 in patients with lung disease. 54 61
19375295 2009
36
Lung deposition of inhaled alpha1-proteinase inhibitor in cystic fibrosis and alpha1-antitrypsin deficiency. 61 54
19251783 2009
37
Expression of MMP-7, MMP-9, TIMP-1 and TIMP-2 mRNA in lung tissue of patients with non-small cell lung cancer (NSCLC) and benign pulmonary disease. 61 54
19596921 2009
38
Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. 54 61
19372250 2009
39
New surfactant protein C gene mutations associated with diffuse lung disease. 61 54
19443464 2009
40
Matrix metalloproteinase-9 deficiency worsens lung injury in a model of bronchopulmonary dysplasia. 61 54
19097983 2009
41
IL1B polymorphisms modulate cystic fibrosis lung disease. 61 54
19431193 2009
42
Association of transforming growth factor beta1 gene polymorphisms and asbestos-induced fibrosis and tumors. 54 61
19349911 2009
43
Defective organellar acidification as a cause of cystic fibrosis lung disease: reexamination of a recurring hypothesis. 61 54
19329540 2009
44
Tumour necrosis factor-alpha processing in interstitial lung disease: a potential role for exogenous proteinase-3. 61 54
19292764 2009
45
[Diagnosis and prediction of lung cancer through different classification techniques with tumor markers]. 54 61
19538834 2009
46
Association of MBL2, TGF-beta1 and CD14 gene polymorphisms with lung disease severity in cystic fibrosis. 54 61
19466271 2009
47
Generation of bleomycin-induced lung fibrosis is independent of IL-16. 54 61
19232499 2009
48
Identification of IFRD1 as a modifier gene for cystic fibrosis lung disease. 54 61
19242412 2009
49
Exhaled nitric oxide levels in alpha-1-antitrypsin PiMZ subjects. 54 61
19019191 2009
50
Gene targeted therapeutics for liver disease in alpha-1 antitrypsin deficiency. 54 61
19707397 2009
Sources

Variations for Lung Disease

About this section
Sources

Expression for Lung Disease

About this section
Search GEO for disease gene expression data for Lung Disease.
Sources

Pathways for Lung Disease

About this section

Pathways related to Lung Disease according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Metabolism of proteins 65
Show member pathways
 13.64 SFTPD SFTPC SFTPB SFTPA2 SFTPA1 SERPINA1
2
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 12.93 TNF SFTPD SFTPA2 IL1B IFIH1 CXCL8
3
Toll-Like receptor Signaling Pathways 64
Show member pathways
 12.57 TNF MUC5B IL1B CXCL8 CFTR
4
IL-17 Family Signaling Pathways 64
Show member pathways
 12.19 TNF MUC5B IL1B CXCL8 CFTR
5
Salmonella infection (KEGG) 36
12.17 TNF IL1B FLNA CXCL8
6
Bacterial infections in CF airways 22
Show member pathways
 11.95 TNF SFTPD SFTPA1 IL1B CXCL8 CFTR
7
Diseases of metabolism 65
Show member pathways
 11.73 SFTPD SFTPC SFTPB SFTPA2 SFTPA1
8
Rheumatoid arthritis 36
11.72 TNF IL1B CXCL8
9
Pertussis 36
11.6 TNF SFTPA2 SFTPA1 IL1B CXCL8
10
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.52 TNF IL1B CXCL8
11
Legionellosis 36
11.46 TNF IL1B CXCL8
12
Malaria 36
11.39 TNF IL1B CXCL8
13
FOXA1 transcription factor network 1
Show member pathways
 11.37 SFTPD SFTPA2 SFTPA1 SERPINA1
14
Interleukin-10 signaling 65
11.36 TNF IL1B CXCL8
15
Monoamine Transport 1
Show member pathways
 11.29 TSC2 TNF IL1B
16
Lung fibrosis 1
11.08 TNF TERT SFTPC SFTPA2 SFTPA1 SERPINA1
17
Surfactant metabolism 65
Show member pathways
 11.07 SFTPD SFTPC SFTPB SFTPA2 SFTPA1 ABCA3
18
Defective CSF2RA causes pulmonary surfactant metabolism dysfunction 4 (SMDP4) 65
Show member pathways
 10.95 SFTPD SFTPC SFTPB SFTPA2 SFTPA1
Sources

GO Terms for Lung Disease

About this section

Cellular components related to Lung Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.1 TNF SFTPD SFTPC SFTPB SFTPA2 SFTPA1
2 extracellular space GO:0005615 9.93 TNF SFTPD SFTPC SFTPB SFTPA2 SFTPA1
3 multivesicular body GO:0005771 9.67 SFTPD SFTPB SFTPA2 SFTPA1
4 collagen trimer GO:0005581 9.63 SFTPD SFTPA2 SFTPA1
5 rough endoplasmic reticulum GO:0005791 9.61 SFTPD SFTPA2 SFTPA1
6 alveolar lamellar body GO:0097208 9.43 SFTPC SFTPB ABCA3
7 multivesicular body lumen GO:0097486 9.4 SFTPC SFTPB
8 lamellar body GO:0042599 9.26 SFTPC SFTPB SFTPA2 SFTPA1
9 clathrin-coated endocytic vesicle GO:0045334 9.02 SFTPD SFTPC SFTPB SFTPA2 SFTPA1

Biological processes related to Lung Disease according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 leukocyte migration GO:0050900 9.81 TNF ITGA3 IL1B ELANE
2 positive regulation of phagocytosis GO:0050766 9.65 TNF SFTPD IL1B
3 toll-like receptor signaling pathway GO:0002224 9.63 SFTPD SFTPA2 SFTPA1
4 positive regulation of interleukin-6 secretion GO:2000778 9.61 TNF IL1B IFIH1
5 positive regulation of chemokine biosynthetic process GO:0045080 9.55 TNF IL1B
6 positive regulation of neuroinflammatory response GO:0150078 9.54 TNF IL1B
7 protein kinase B signaling GO:0043491 9.54 TSC2 TNF IL1B
8 regulation of establishment of endothelial barrier GO:1903140 9.52 TNF IL1B
9 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.5 TNF TERT IL1B
10 cellular protein metabolic process GO:0044267 9.5 SFTPD SFTPC SFTPB SFTPA2 SFTPA1 SERPINA1
11 positive regulation of fever generation GO:0031622 9.49 TNF IL1B
12 developmental process GO:0032502 9.43 SFTPD SFTPA2 SFTPA1
13 sequestering of triglyceride GO:0030730 9.4 TNF IL1B
14 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.16 TNF IL1B
15 respiratory gaseous exchange GO:0007585 9.02 SFTPD SFTPC SFTPB SFTPA2 SFTPA1

Molecular functions related to Lung Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protease binding GO:0002020 9.26 TNF SERPINA1 ITGA3 ELANE
2 monosaccharide binding GO:0048029 8.8 SFTPD SFTPA2 SFTPA1
Sources

Sources for Lung Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....